KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-cash Items (2016 - 2025)

Sarepta Therapeutics (SRPT) has 13 years of Non-cash Items data on record, last reported at $425.0 million in Q4 2024.

  • For Q4 2024, Non-cash Items rose 7041.17% year-over-year to $425.0 million; the TTM value through Dec 2024 reached $425.0 million, up 7041.17%, while the annual FY2024 figure was $425.0 million, 7041.17% up from the prior year.
  • Non-cash Items reached $425.0 million in Q4 2024 per SRPT's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $557.9 million in Q4 2022 and bottomed at $2.0 million in Q4 2020.
  • Average Non-cash Items over 5 years is $198.7 million, with a median of $6.0 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: soared 21931.22% in 2022, then tumbled 98.93% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $2.0 million in 2020, then increased by 25.35% to $2.5 million in 2021, then skyrocketed by 21931.22% to $557.9 million in 2022, then crashed by 98.93% to $6.0 million in 2023, then soared by 7041.17% to $425.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $425.0 million in Q4 2024, $6.0 million in Q4 2023, and $557.9 million in Q4 2022.